4D Molecular Therapeutics, Inc. 8-K

What Happened
4D Molecular Therapeutics, Inc. (4DMT) announced its financial results for the quarter ended March 31, 2026 in an 8-K filed May 7, 2026. The company furnished a press release titled “4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones” summarizing its quarterly results and operational updates.

Key Details

• Filing date: May 7, 2026 (Form 8-K, Item 2.02: Results of Operations and Financial Condition).
• Reporting period: three months ended March 31, 2026 (Q1 2026).
• Press release furnished as Exhibit 99.1; interactive XBRL cover page included as Exhibit 104.
• Form 8-K signed by Kristian Humer, Chief Financial Officer, on behalf of 4D Molecular Therapeutics.

Why It Matters
This filing signals that 4DMT has released its quarterly earnings and operational update — information investors use to assess recent performance, cash position, and progress toward upcoming milestones. Retail investors should read the furnished press release (Exhibit 99.1) for the company’s reported revenue, expenses, net income/loss, cash runway, and any stated timelines for programs or catalysts that could affect the stock.